Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of June 30, 2018:
- Issued Share Capital: 5,374,473,060 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,959,867,110.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of the share capital and voting rights as of June 30, 2018, intended for shareholder notification calculations.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. Its sole purpose is to inform shareholders of the denominator to be used for determining notification requirements under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,959,867,110) against internal holdings to determine if disclosure thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (414,605,950) to ensure accurate calculation of outstanding voting shares.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for financial performance data.